Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option BioPharma DiveAt a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments.Metabolic & GLP-1Read full story pharminent June 8, 2026 (Last updated: June 8, 2026) BioPharma Dive At a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments. Metabolic & GLP-1 Read full story Post navigation Previous: ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reductionNext: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026